Key Stats for Eli Lilly Stock
- Pre-market price change for Eli Lilly stock today: -2%
- $LLY Stock Price as of Mar. 27: $878
- 52-Week High: $1134
- $LLY Stock Price Target: $1209
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock is getting a boost today after the company announced a $2.75 billion deal with Hong Kong-based Insilico Medicine to bring AI-developed drugs to the global market.
- The deal gives Insilico $115 million upfront.
- The rest is tied to regulatory and commercial milestones, as well as future sales royalties.
Insilico has built a pipeline of at least 28 drugs using generative AI, and nearly half are already in clinical trials.
Eli Lilly CEO David Ricks recently attended a high-level forum in Beijing, weeks after the company announced plans to invest $3 billion in China over the next decade.
The two companies aren’t starting from scratch here.
They signed an AI-based software licensing agreement back in 2023, so this deal builds on an existing relationship.
Insilico will also join Lilly’s Gateway Labs, a biotech development community, as part of the arrangement.
Andrew Adams, Lilly’s Group VP of Molecule Discovery, described Insilico’s AI-powered drug discovery as “a powerful complement” to Lilly’s clinical development.
The idea is simple: AI can find and synthesize new drug candidates faster than traditional methods, potentially speeding up Lilly’s already busy pipeline.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
Eli Lilly stock has pulled back around 19% this year, so any pipeline news that signals future growth tends to get attention.
This deal fits neatly into Lilly’s broader strategy of using technology to find new drugs faster and cheaper.
With Eli Lilly stock still sitting well below its 52-week high, investors looking for a re-entry point may find today’s news encouraging.
Eli Lilly stock continues to attract interest from long-term investors who see the company’s AI and obesity drug pipeline as major growth drivers heading into 2026 and beyond.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
